Glucocorticoids and estrogens modulate the NF-κB pathway differently in the micro- and macrovasculature

• Published in: Medical hypotheses 2013-12, Vol.81 (6), p.1078-1082
• Main Authors: Edgar, Abarca-Rojano, Judith, Pacheco-Yépez, Elisa, Drago-Serrano Maria, Rafael, Campos-Rodríguez
• Format: Article
• Language: English
• Subjects: Endothelial Cells - metabolism; Endothelial Cells - physiology; Estrogens - metabolism; Glucocorticoids - metabolism; Humans; Internal Medicine; Microvessels - metabolism; Microvessels - physiology; Models, Biological; NF-kappa B - metabolism; Receptors, Estrogen - metabolism; Receptors, Glucocorticoid - metabolism; Signal Transduction - physiology
• ISSN: 0306-9877; 1532-2777
• DOI: 10.1016/j.mehy.2013.10.007

Abstract Estrogens and glucocorticoids have synergistic effects in the micro and macrovasculature of endothelial cells (ECs), having pro-inflammatory effects in the former and inhibiting the expression of adhesion molecules in the latter. The molecular basis of these effects in the endothelium has not yet been clarified. We postulate that the ECs of the micro- and macrovasculature have different non-genomic mechanisms that regulate levels of preexisting complexes of glucocorticoids and estrogens with their respective receptors. Since these receptors are regulated by NF-κB, their expression could be critical to the activation of a pro- or anti-inflammatory response. In the macrovasculature the synergistic effects of estrogens and glucocorticoids on ECs may be through the inhibition of NF-κB, leading to the inhibition of the expression of inflammatory molecules. It seems likely that glucocorticoid-receptor and estrogen-receptor complexes directly bind to NF-κB proteins in the macrovasculature, resulting in the inhibition of an excessive proinflammatory response. Further insights into these processes may help clarify the role of the endothelial cells of different vascular beds during the inflammatory response and chronic inflammation, and thus contribute to the design of more effective therapeutic strategies for the prevention of diseases related to inflammation, including atherosclerosis, systemic lupus erythematosus and rheumatoid arthritis.